CBRNE - Glanders and Melioidosis 

  • Author: Paul P Rega, MD, FACEP; Chief Editor: Robert G Darling, MD, FACEP   more...
 
Updated: Feb 10, 2011
 

Background

Glanders and melioidosis are related diseases produced by bacteria of the Burkholderia species, which are gram-negative rods. They produce similar symptoms and have similar pathophysiologic consequences. Glanders and melioidosis are of interest because of significant study for potential weaponization by the United States and other countries in the past. During World War I, glanders was believed to have been spread to infect large numbers of Russian horses and mules on the Eastern Front. The Japanese infected horses, civilians, and prisoners of war during World War II. The United States studied this agent as a possible biological warfare (BW) weapon in 1943-1944 but did not weaponize it. The former Soviet Union is believed to have been interested in glanders as a potential BW weapon as well.

Burkholderia mallei (nonmotile, nonsporulating, obligate aerobic, gram-negative bacillus) is the causative agent of glanders, primarily a disease of animals such as horses, mules, and donkeys. Glanders has been only a rare and sporadic disease in humans, and no epidemics have been reported. In China during World War II, 30% of the tested horses were infected with glanders, but human cases were rare. The reason for the low transmission rate is not known. In the human population, it typically is found in those with close and frequent contact with infected animals, such as veterinarians, animal caretakers, abattoir workers, and laboratory personnel.

Melioidosis, also known as Whitmore disease, is caused by the bacterium Burkholderia pseudomallei (a motile, aerobic, non–spore-forming bacillus). It is clinically similar to glanders disease, although the epidemiology differs. The bacteria thrive in tropical climates, and the disease is endemic in Southeast Asia and Australia, but it is found in the Middle East, India, and China (essentially tropical areas between latitudes 20 degrees north and south). Sporadic melioidosis cases have been reported in the United States (typically 0-5 cases per year, usually among immigrants and travelers). However, the worldwide incidence appears to be increasing as a result of increased travel and epidemiological sophistication. Both humans and other susceptible animals may contract the disease.

Both organisms are considered potential biological warfare (BW) agents, especially in the aerosolized form. In fact, because of the fact that they are highly infectious especially by inhalation and because of their resistance to routine antibiotics, both bacteria have been classified as category B priority pathogens by the National Institutes of Health and the Centers for Disease Control and Prevention (CDC).[1]

Next

Pathophysiology

Glanders is caused by B mallei (formerly Pseudomonas mallei). The bacteria only exist in infected susceptible hosts and are not found in water, soil, or plants. In nature, humans typically acquire glanders from equids via direct contact with broken skin or mucous membranes. While transmission through intact skin has been reported, it is not well documented. A secondary mode of transmission can be through inhalation of droplets from an infected equid or patient. Once in the host, synthesis and release of certain toxins occur. Usually, the amount is insignificant, and no clinical disease process ensues. However, if a large quantity of the organism is incorporated, the amount of toxin is sufficient to cause specific symptoms. Antibiotics are of little use. The toxins include pyocyanin (blue-green pigment that interferes with the terminal electron transfer system), lecithinase (causes cell lysis by degrading lecithin in certain cell membranes), collagenase, lipase, and hemolysin.

Melioidosis is an infectious disease caused by B pseudomallei (formerly Pseudomonas pseudomallei). The organism is distributed widely in the soil and water of the tropics. It is spread to humans through direct contact with a contaminated source, especially during the rainy season. The disease usually occurs in the fourth and fifth decades of life, especially among those who have chronic comorbidities such as diabetes, alcoholism, immunosuppression, and renal failure. B pseudomallei is considered a good candidate as a bioweapon because it is easily available in the tropics, it is fairly easy to cultivate, it is sturdy, and it has a high potential to become bacteremic, thereby increasing morbidity and mortality. The incubation period in naturally acquired infections can vary from days to months to years. The incubation period after an aerosol attack is expected to be from 10-14 days.

Glanders and melioidosis produce similar clinical syndromes.

Localized form

Bacteria enter the skin through a laceration or abrasion, and a local infection with ulceration develops. The incubation period is 1-5 days. Swollen lymph glands may develop. Bacteria that enter the host through mucous membranes can cause increased mucus production in the affected areas.

Pulmonary form

When bacteria are aerosolized and enter the respiratory tract via inhalation or hematogenous spread, pulmonary infections may develop. Pneumonia, pulmonary abscesses, and pleural effusions can occur. The incubation period is 10-14 days. With inhalational melioidosis, cutaneous abscesses may develop and take months to appear.

Septicemia

When bacteria is disseminated in the bloodstream in glanders, it is usually fatal within 7-10 days. The septicemia that develops affects multiple systems, and cutaneous, hepatic, and splenic involvement may occur. With melioidosis, bacteremia is observed with chronically ill patients (eg, patients with HIV, patients with diabetes). They develop respiratory distress, headaches, fever, diarrhea, pus-filled lesions on the skin, and abscesses throughout the body. Septicemia may be overwhelming, with a 90% fatality rate and death occurring within 24-48 hours.

Chronic form

The chronic form involves multiple abscesses, which may affect the liver, spleen, skin, or muscles. This form also is known as farcy in glanders disease. Melioidosis, in addition to this chronic form, can become reactive many years after the primary infection.

Previous
Next

Epidemiology

Frequency

United States

Glanders was eliminated from US domesticated animals in the 1940s. One recent human case of glanders in a laboratory worker occurred in 2000. This is the first human case reported in the United States since 1945.[2]

A few isolated cases of melioidosis have occurred in the United States. Confirmed cases range from 0-5 each year and occur among travelers, immigrants, and intravenous drug users.[3]

International

Glanders is endemic in Africa, Asia, the Middle East, Central America, and South America.

Melioidosis is endemic in Southeast Asia and northern Australia. Nevertheless, even in these zones, the diagnosis may be delayed.[4] However, it has been observed in the South Pacific, Africa, India, the Middle East, Central America, and South America.

In fact, in India, it has acquired the status of a newly emerging infectious disease.[5] One study in India involving a series of patients with melioidosis revealed that skin and soft-tissue involvement (16%), liver abscess (16%), and bone and joint involvement (16%) were the most common presentations of this disease in patients with diabetes. Septicemia and major organ failure resulting in death was not uncommon.[6]

Mortality/Morbidity

Glanders is primarily zoonotic. It is rare in humans, and no epidemics have been reported. The mortality rate in the pulmonary form of glanders is 90-95% if untreated and 40% if treated. The mortality rate in the septicemic form of glanders is greater than 95% if untreated and 50% if treated. The mortality rate in the cutaneous form of glanders is 90-95% if it becomes systemic and if untreated but 50% if properly treated. For the chronic form of glanders, the mortality rate may be 50% despite treatment.

Melioidosis has had a reported mortality rate up to 90% if disseminated septicemia is present. In Australia, the mortality rate is 19%, whereas in Thailand it is 50%. It is most widespread in Thailand, where in one hospital, it was responsible for 19% of community-acquired sepsis and 40% of deaths from community-acquired septicemia.[7] The fatality rate of melioidosis is greater in people with specific comorbidities, such as diabetes mellitus, renal dysfunction, or chronic pulmonary disease, and in people who are immunosuppressed for one reason or another.

Previous
 
 
Contributor Information and Disclosures
Author

Paul P Rega, MD, FACEP  Assistant Professor, Department of Public Health and Preventive Medicine, The University of Toledo College of Medicine; Assistant Professor, Department of Emergency Medicine, The University of Toledo College of Medicine; Director of Emergency Medicine Education and Disaster Management, OMNI Health Services

Paul P Rega, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Jerry L Mothershead, MD  Medical Readiness Consultant, Medical Readiness and Response Group, Battelle Memorial Institute; Advisor, Technical Advisory Committee, Emergency Management Strategic Healthcare Group, Veteran's Health Administration; Adjunct Associate Professor, Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences

Jerry L Mothershead, MD is a member of the following medical societies: American College of Emergency Physicians and National Association of EMS Physicians

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Rick Kulkarni, MD 

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Robert G Darling, MD, FACEP  Adjunct Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine

Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, American Telemedicine Association, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

References
  1. Bondi SK, Goldberg JB. Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei. Expert Rev Vaccines. Nov 2008;7(9):1357-65. [Medline].

  2. Centers for Disease Control and Prevention. Laboratory-acquired human glanders--Maryland, May 2000. MMWR Morb Mortal Wkly Rep. Jun 23 2000;49(24):532-5. [Medline].

  3. Duplessis C, Maguire JD. Melioidosis masquerading as community-acquired pneumonia: a case report demonstrating efficacy of intrapleural fibrinolytic therapy. J Travel Med. Jan-Feb 2009;16(1):74-7. [Medline].

  4. Overtoom R, Khieu V, Hem S, Cavailler P, Te V, Chan S, et al. A first report of pulmonary melioidosis in Cambodia. Trans R Soc Trop Med Hyg. Dec 2008;102 Suppl 1:S21-5. [Medline].

  5. Valsalan R, Seshadri S, Pandit VR. Melioidosis masquerading as enteric fever. Trans R Soc Trop Med Hyg. Dec 2008;102 Suppl 1:S117-8. [Medline].

  6. Mukhopadhyay C, Chawla K, Krishna S, Nagalakshmi N, Rao SP, Bairy I. Emergence of Burkholderia pseudomallei and pandrug-resistant non-fermenters from southern Karnataka, India. Trans R Soc Trop Med Hyg. Dec 2008;102 Suppl 1:S12-7. [Medline].

  7. Montgomery S. Burkholderia pseudomallei (melioidosis) Attack. In: Ciottone GR, Anderson PD, Auf Der Heide E, Darling RG, Jacoby I, Noji E, Suner S, eds. Disaster Medicine. 3rd ed. Philadelphia, PA: Mosby/Elsevier; 2006:chap 115; 650-652.

  8. Muttarak M, Peh WC, Euathrongchit J, Lin SE, Tan AG, Lerttumnongtum P, et al. Spectrum of imaging findings in melioidosis. Br J Radiol. Dec 19 2008;[Medline].

  9. Dance DA. Melioidosis as an emerging global problem. Acta Trop. Feb 5 2000;74(2-3):115-9. [Medline].

  10. Graber MA. Burkholderia mallei (glanders) attack. In: Ciottone GR, Anderson PD, Auf Der Heide E, Darling RG, Jacoby I, Noji E, Suner S, eds. Disaster Medicine. 3rd ed. Philadelphia, PA: Mosby/Elsevier; 2006:chap 114; 647-649.

  11. CIDRAP News. US awards contracts in hunt for versatile biodefense drug. September 23, 2008. CIDRAP, Center for Infectious Disease Research & Policy. Available at http://www.cidrap.umn.edu/cidrap/content/bt/bioprep/news/sep2308contracts-jw.html. Accessed February 22, 2009.

  12. Goodyear A, Kellihan L, Bielefeldt-Ohmann H, Troyer R, Propst K, Dow S. Protection From Pneumonic Burkholderia Infection by Inhalational Immunotherapy. Infect Immun. Jan 29 2009;[Medline].

  13. Sarkar-Tyson M, Titball RW. Progress toward development of vaccines against melioidosis: A review. Clin Ther. Aug 2010;32(8):1437-45. [Medline].

  14. CDC Strategic Planning Workgroup. Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Recomm Rep. Apr 21 2000;49(RR-4):1-14. [Medline].

  15. Centers for Disease Control and Prevention. Imported melioidosis--South Florida, 2005. MMWR Morb Mortal Wkly Rep. Aug 18 2006;55(32):873-6. [Medline].

  16. Institute for International Cooperation in Animal Biologics. Glanders. Last updated January 2004. The Center for Food Security & Public Health (Iowa State University). Available at www.cfsph.iastate.edu/Factsheets/pdfs/glanders.pdf. Accessed June 13, 2007.

  17. Institute for International Cooperation in Animal Biologics. Melioidosis. Last updated October 2005. The Center for Food Security & Public Health (Iowa State University). Available at www.cfsph.iastate.edu/Factsheets/pdfs/melioidosis.pdf. Accessed June 13, 2007.

  18. Ko WC, Cheung BM, Tang HJ, Shih HI, Lau YJ, Wang LR, et al. Melioidosis outbreak after typhoon, southern Taiwan. Emerg Infect Dis. Jun 2007;13(6):896-8. [Medline].

  19. McGovern TW, Christopher GW, Eitzen EM. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol. Mar 1999;135(3):311-22. [Medline].

  20. Short BH. Melioidosis: an important emerging infectious disease - a military problem?. ADF Health. Apr 2002;3:13-21.

  21. Thummakul T, Wilde H, Tantawichien T. Melioidosis, an environmental and occupational hazard in Thailand. Mil Med. Sep 1999;164(9):658-62. [Medline].

  22. USAMRIID. Glanders and melioidosis. In: Biological Warfare and Terrorism: Medical Issues and Response. 2000. 21-25.

  23. USAMRIID. Glanders and Melioidosis. Accessed January 28, 2005. Available at http://navymedicine.med.navy.mil/Files/Media/directives/5042.pdf.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.